EZH2 is associated with poor prognosis in head-and-neck squamous cell carcinoma via regulating the epithelial-to-mesenchymal transition and chemosensitivity

Oral Oncology

Volumn 52, Issue , 2016, Pages 66-74

  Chang, Jae Won ^a   Gwak, Seo Young ^a   Shim, Geun Ae ^a   Liu, Lihua ^a   Lim, Young Chang ^b   Kim, Jin Man ^a   Jung, Min Gyu ^a   Koo, Bon Seok ^a  

^a Chungnam National University   (South Korea)

^b Konkuk University School of Medicine   (South Korea)

Author keywords

Chemosensitivity; Enhancer zeste homolog 2 (EZH2); Epithelial to mesenchymal transition (EMT); Head and neck squamous cell carcinoma (HNSCC); Prognosis

Indexed keywords

BIOLOGICAL MARKER; CISPLATIN; NERVE CELL ADHESION MOLECULE; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR EZH2; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR SNAIL; UVOMORULIN; VIMENTIN; ANTINEOPLASTIC AGENT; CADHERIN; EZH2 PROTEIN, HUMAN; POLYCOMB REPRESSIVE COMPLEX 2;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CANCER RISK; CANCER STAGING; CELL INVASION ASSAY; CELL MIGRATION; CELL MIGRATION ASSAY; CELL PROLIFERATION; CHEMOSENSITIVITY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; EPIGENETICS; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; KAPLAN MEIER METHOD; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; RETROSPECTIVE STUDY; RNA INTERFERENCE; SURVIVAL RATE; TISSUE MICROARRAY; TREATMENT RESPONSE; UPREGULATION; WESTERN BLOTTING; CARCINOMA, SQUAMOUS CELL; GENETIC EPIGENESIS; HEAD AND NECK NEOPLASMS; METABOLISM; MIDDLE AGED; PHYSIOLOGY; PROGNOSIS; SURVIVAL ANALYSIS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CADHERINS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; ENHANCER OF ZESTE HOMOLOG 2 PROTEIN; EPIGENESIS, GENETIC; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; POLYCOMB REPRESSIVE COMPLEX 2; PROGNOSIS; RETROSPECTIVE STUDIES; RNA, SMALL INTERFERING; SURVIVAL ANALYSIS; VIMENTIN;

EID: 84947301034     PISSN: 13688375     EISSN: 18790593     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2015.11.002     Document Type: Article

References (35)

1. N. Vigneswaran, and M.D. Williams Epidemiologic trends in head and neck cancer and aids in diagnosis Oral Maxillofac Surg Clin North Am 26 2014 123 141
2. M. Zheng, Y.P. Jiang, W. Chen, K.D. Li, X. Liu, S.Y. Gao, and et al. Snail and slug collaborate on EMT and tumor metastasis through miR-101-mediated EZH2 axis in oral tongue squamous cell carcinoma Oncotarget 6 2015 6797 6810
3. J.D. Howard, B. Lu, and C.H. Chung Therapeutic targets in head and neck squamous cell carcinoma: identification, evaluation, and clinical translation Oral Oncol 48 2012 10 17
4. L. Zhao, Y. Yu, J. Wu, J. Bai, Y. Zhao, C. Li, and et al. Role of EZH2 in oral squamous cell carcinoma carcinogenesis Gene 537 2014 197 202
5. E. Vire, C. Brenner, R. Deplus, L. Blanchon, M. Fraga, C. Didelot, and et al. The Polycomb group protein EZH2 directly controls DNA methylation Nature 439 2006 871 874
6. M.T. McCabe, and C.L. Creasy EZH2 as a potential target in cancer therapy Epigenomics 6 2014 341 351
7. F. Crea, L. Fornaro, G. Bocci, L. Sun, W.L. Farrar, A. Falcone, and et al. EZH2 inhibition: targeting the crossroad of tumor invasion and angiogenesis Cancer Metastasis Rev 31 2012 753 761
8. W. Zhou, J. Wang, W.Y. Man, Q.W. Zhang, and W.G. Xu SiRNA silencing EZH2 reverses cisplatin-resistance of human non-small cell lung and gastric cancer cells Asian Pac J Cancer Prev 16 2015 2425 2430
9. L. Liu, J. Guo, L. Yu, J. Cai, T. Gui, H. Tang, and et al. MiR-101 regulates expression of EZH2 and contributes to progression of and cisplatin resistance in epithelial ovarian cancer Tumour Biol 35 2014 12619 12626
10. Y. Zhang, G. Liu, C. Lin, G. Liao, and B. Tang Silencing the EZH2 gene by RNA interference reverses the drug resistance of human hepatic multidrug-resistant cancer cells to 5-Fu Life Sci 92 2013 896 902
11. G. Sauter, R. Simon, and K. Hillan Tissue microarrays in drug discovery Nat Rev Drug Discovery 2 2003 962 972
12. B.S. Koo, S.H. Lee, J.M. Kim, S. Huang, S.H. Kim, Y.S. Rho, and et al. Oct4 is a critical regulator of stemness in head and neck squamous carcinoma cells Oncogene 34 2015 2317 2324
13. C.C. Huang, J.T. Qiu, M.L. Kashima, R.J. Kurman, and T. Wu Generation of type-specific probes for the detection of single-copy human papillomavirus by a novel in situ hybridization method Modern Pathol: Off J US Can Acad Pathol Inc 11 1998 971 977
14. J.W. Chang, S.U. Kang, Y.S. Shin, K.I. Kim, S.J. Seo, S.S. Yang, and et al. Non-thermal atmospheric pressure plasma inhibits thyroid papillary cancer cell invasion via cytoskeletal modulation, altered MMP-2/-9/uPA activity PLoS ONE 9 2014 e92198
15. W. Cao, R.H. Younis, J. Li, H. Chen, R. Xia, L. Mao, and et al. EZH2 promotes malignant phenotypes and is a predictor of oral cancer development in patients with oral leukoplakia Cancer Prev Res (Phila) 4 2011 1816 1824
16. C. Wang, X. Liu, Z. Chen, H. Huang, Y. Jin, A. Kolokythas, and et al. Polycomb group protein EZH2-mediated E-cadherin repression promotes metastasis of oral tongue squamous cell carcinoma Mol Carcinog 52 2013 229 236
17. J. Knezevic, A.D. Pfefferle, I. Petrovic, S.B. Greene, C.M. Perou, and J.M. Rosen Expression of miR-200c in claudin-low breast cancer alters stem cell functionality enhances chemosensitivity and reduces metastatic potential Oncogene 2015
18. W. Cao, Z. Feng, Z. Cui, C. Zhang, Z. Sun, L. Mao, and et al. Up-regulation of enhancer of zeste homolog 2 is associated positively with cyclin D1 overexpression and poor clinical outcome in head and neck squamous cell carcinoma Cancer 118 2012 2858 2871
19. R. Banerjee, R.S. Mani, N. Russo, C.S. Scanlon, A. Tsodikov, X. Jing, and et al. The tumor suppressor gene rap1GAP is silenced by miR-101-mediated EZH2 overexpression in invasive squamous cell carcinoma Oncogene 30 2011 4339 4349
20. K. Kidani, M. Osaki, T. Tamura, K. Yamaga, K. Shomori, K. Ryoke, and et al. High expression of EZH2 is associated with tumor proliferation and prognosis in human oral squamous cell carcinomas Oral Oncol 45 2009 39 46
21. Y. Wu, L. Zhang, L. Zhang, Y. Wang, H. Li, X. Ren, and et al. Long non-coding RNA HOTAIR promotes tumor cell invasion and metastasis by recruiting EZH2 and repressing E-cadherin in oral squamous cell carcinoma Int J Oncol 46 2015 2586 2594
22. Y.C. Lim, H.J. Kang, and J.H. Moon C-Met pathway promotes self-renewal and tumorigenecity of head and neck squamous cell carcinoma stem-like cell Oral Oncol 50 2014 633 639
23. G. Wang, Y. Sun, Y. He, C. Ji, B. Hu, and Y. Sun MiR-26a promoted by interferon-alpha inhibits hepatocellular carcinoma proliferation and migration by blocking EZH2 Genet Test Mol Biomark 19 2015 30 36
24. C. Lin, F. Huang, Q.Z. Li, and Y.J. Zhang MiR-101 suppresses tumor proliferation and migration, and induces apoptosis by targeting EZH2 in esophageal cancer cells Int J Clin Exp Pathol 7 2014 6543 6550
25. J. Chen, H. Xu, X. Zou, J. Wang, Y. Zhu, H. Chen, and et al. Snail recruits Ring1B to mediate transcriptional repression and cell migration in pancreatic cancer cells Cancer Res 74 2014 4353 4363
26. D.L. Chen, D.S. Zhang, Y.X. Lu, L.Z. Chen, Z.L. Zeng, M.M. He, and et al. MicroRNA-217 inhibits tumor progression and metastasis by downregulating EZH2 and predicts favorable prognosis in gastric cancer Oncotarget 6 2015 10868 10879
27. L.R. Bohrer, S. Chen, T.C. Hallstrom, and H. Huang Androgens suppress EZH2 expression via retinoblastoma (RB) and p130-dependent pathways: a potential mechanism of androgen-refractory progression of prostate cancer Endocrinology 151 2010 5136 5145
28. Z.Y. Rao, M.Y. Cai, G.F. Yang, L.R. He, S.J. Mai, W.F. Hua, and et al. EZH2 supports ovarian carcinoma cell invasion and/or metastasis via regulation of TGF-beta1 and is a predictor of outcome in ovarian carcinoma patients Carcinogenesis 31 2010 1576 1583
29. Q. Cao, J. Yu, S.M. Dhanasekaran, J.H. Kim, R.S. Mani, S.A. Tomlins, and et al. Repression of E-cadherin by the polycomb group protein EZH2 in cancer Oncogene 27 2008 7274 7284
30. L.O. Almeida, A.C. Abrahao, L.K. Rosselli-Murai, F.S. Giudice, C. Zagni, A.M. Leopoldino, and et al. NFkappaB mediates cisplatin resistance through histone modifications in head and neck squamous cell carcinoma (HNSCC) FEBS Open Bio 4 2014 96 104
31. H. Wang, Y. Yu, C. Chen, Q. Wang, T. Huang, F. Hong, and et al. Involvement of enhancer of zeste homolog 2 in cisplatinresistance in ovarian cancer cells by interacting with several genes Mol Med Rep 2015
32. C. Xu, K. Hao, H. Hu, Z. Sheng, J. Yan, Q. Wang, and et al. Expression of the enhancer of zeste homolog 2 in biopsy specimen predicts chemoresistance and survival in advanced non-small cell lung cancer receiving first-line platinum-based chemotherapy Lung Cancer 86 2014 268 273
33. F. Oshita, Y. Kameda, K. Nishio, G. Tanaka, K. Yamada, I. Nomura, and et al. Increased expression levels of cyclin-dependent kinase inhibitor p27 correlate with good responses to platinum-based chemotherapy in non-small cell lung cancer Oncol Rep 7 2000 491 495
34. A.V. Ougolkov, V.N. Bilim, and D.D. Billadeau Regulation of pancreatic tumor cell proliferation and chemoresistance by the histone methyltransferase enhancer of zeste homologue 2 Clin Cancer Res 14 2008 6790 6796
35. I.M. Bachmann, O.J. Halvorsen, K. Collett, I.M. Stefansson, O. Straume, S.A. Haukaas, and et al. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast J Clin Oncol: Off J Am Soc Clin Oncol 24 2006 268 273